Skip to content

Study · Randomized controlled trial · n = 978 · 2015

7 results

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.

D'Alessio D, Häring HU, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain MP, Vincent M, Pilorget V, Yki-Järvinen H

Diabetes, obesity & metabolism7 Dec 2014Cited by 45 (Europe PMC)

PMID25359159 (opens in a new tab)DOI10.1111/dom.12406 (opens in a new tab)PepBankPUB-25359159
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, similar proportions reached HbA1c below 7% with liraglutide and glargine (45.9% vs 48.4%), so superiority of glargine was not shown.

    In plain wordsIn adults with poorly controlled type 2 diabetes, about the same share reached the HbA1c target with liraglutide as with glargine insulin.

    Peptide
    Liraglutide
    Outcome
    No significant changeProportion reaching HbA1c <7%
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Measurements

    HbA1c <7% responders
    45.9%
    liraglutide
    HbA1c <7% responders
    48.4%
    glargine

    Source sentences

    Summary
    Similar numbers of subjects in both groups attained an HbA1c level of <7% (48.4 vs. 45.9%); therefore, superiority of glargine over liraglutide was not observed (p = 0.44).
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, liraglutide reduced HbA1c, but by less than glargine.

    In plain wordsIn adults with poorly controlled type 2 diabetes, liraglutide lowered HbA1c, but glargine insulin lowered it a little more.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.79%
    liraglutide
    HbA1c change
    −1.94%
    glargine

    Source sentences

    Summary
    Subjects treated with glargine had greater reductions of HbA1c [-1.94% (0.05) and -1.79% (0.05); p = 0.019]
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, fasting plasma glucose was reduced less with liraglutide than with glargine.

    In plain wordsIn adults with poorly controlled type 2 diabetes, glargine insulin lowered fasting blood sugar more than liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose
    7.9 mmol/L
    liraglutide
    Fasting plasma glucose
    6.2 mmol/L
    glargine

    Source sentences

    Summary
    fasting plasma glucose [6.2 (1.6) and 7.9 (2.2) mmol/L; p < 0.001] than those receiving liraglutide.
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with poorly controlled type 2 diabetes, liraglutide caused more gastrointestinal treatment-emergent adverse events than glargine.

    In plain wordsIn adults with poorly controlled type 2 diabetes, liraglutide caused more stomach and gut side effects than glargine insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal treatment-emergent adverse events
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The liraglutide group reported a greater number of gastrointestinal treatment-emergent adverse events (p < 0.001).
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with poorly controlled type 2 diabetes, mean weight fell by 3.0 kg with liraglutide while it rose by 2.0 kg with glargine.

    In plain wordsIn adults with poorly controlled type 2 diabetes, people on liraglutide lost weight while people on glargine insulin gained weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −3 kg
    liraglutide
    Weight change
    2 kg
    glargine

    Source sentences

    Summary
    The mean (s.d.) weight change was +2.0 (4.0) kg for glargine and -3.0 (3.6) kg for liraglutide (p < 0.001).
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.
  6. 06HumanRandomized controlled trialSafety outcome

    In adults with poorly controlled type 2 diabetes, symptomatic hypoglycaemia was less common with liraglutide than with glargine.

    In plain wordsIn adults with poorly controlled type 2 diabetes, low blood sugar with symptoms was less common with liraglutide than with glargine insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseSymptomatic hypoglycaemia
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Symptomatic hypoglycaemia was more common with glargine (p < 0.001).
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.
  7. 07HumanRandomized controlled trialSafety outcome

    In adults with poorly controlled type 2 diabetes, more subjects withdrew because of adverse events with liraglutide than with glargine.

    In plain wordsIn adults with poorly controlled type 2 diabetes, more people stopped liraglutide because of side effects than stopped glargine insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseWithdrawal due to adverse events
    Study

    n = 978

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    A greater number of subjects in the liraglutide arm withdrew as a result of adverse events (p < 0.001).
    2 context sentences
    Summary · context
    This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%.
    Summary · context
    Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.